Diamond BioFund Inc. AI Stock Analysis
Diamond BioFund Inc. (6901) AI Stock Analysis
Diamond BioFund Inc.
(TWSE:6901)
The score is held back primarily by weak financial performance: no recurring revenue, three straight annual losses, negative operating and free cash flow in 2025, and a capital base that has shrunk roughly 28% since 2023. The main strength is an exceptionally conservative balance sheet, with almost no debt and equity funding nearly all assets, which limits solvency risk and provides capacity to absorb further portfolio losses. Technicals reinforce caution, with the price below all key moving averages and a negative MACD, though deeply oversold RSI and Stochastic readings suggest the selling may be stretched. A low P/E offers optical value but is unreliable given volatile, mark-driven earnings, and the lack of a dividend provides no income offset.
Diamond BioFund Inc. (6901) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 11.86B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.77M
- Price to Earnings (P/E)
- 4.1
- Beta (1Y)
- 0.44
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 29
- Sector
- General
- Sector Strength
- 55
- Industry
- Asset Management
Diamond BioFund Inc. Business Overview & Revenue Model
Company Description
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipme...
Diamond BioFund Inc. Financial Statement Overview
Summary
Weak and highly erratic fundamentals. The income statement (24) shows effectively no recurring revenue and three consecutive loss years (-NT$2.58bn in 2023, -NT$2.52bn in 2024, -NT$1.17bn in 2025), with results driven entirely by portfolio valuation swings. Cash flow (32) has been negative in four of the last six years, including -NT$166m operating and free cash flow in 2025 after a strong +NT$1.14bn in 2024. The balance sheet (66) is the clear offset: debt of just NT$94m against NT$9.22bn equity (~0.01x D/E) and equity funding ~98.5% of assets leaves minimal solvency risk, though capital has eroded ~28% since 2023 and ROE remains negative at about -12.7%.
Income Statement
24NegativeBalance Sheet
66PositiveCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.13B | -596.00K | 0 | 0 | 0 | 0 |
| Gross Profit | 3.10B | -28.58M | 0 | 0 | 0 | 0 |
| EBITDA | 2.94B | -1.14B | -2.36B | -2.57B | 892.83M | 2.97B |
| Net Income | 2.92B | -1.17B | -2.52B | -2.58B | 797.78M | 2.85B |
Balance Sheet | ||||||
| Total Assets | 12.44B | 9.36B | 10.67B | 13.04B | 11.19B | 10.62B |
| Cash, Cash Equivalents and Short-Term Investments | 2.53B | 3.89B | 5.13B | 9.65B | 10.74B | 10.09B |
| Total Debt | 81.72M | 93.93M | 117.83M | 129.01M | 3.67M | 41.99M |
| Total Liabilities | 126.00M | 137.79M | 301.55M | 179.74M | 144.06M | 230.82M |
| Stockholders Equity | 12.31B | 9.22B | 10.37B | 12.86B | 11.05B | 10.39B |
Cash Flow | ||||||
| Free Cash Flow | -77.12M | -166.11M | 1.12B | -214.93M | 471.04M | -300.42M |
| Operating Cash Flow | -76.88M | -165.92M | 1.14B | -195.82M | 473.09M | -300.42M |
| Investing Cash Flow | -410.42M | 2.80B | -3.12B | -2.40B | 2.48M | 114.84M |
| Financing Cash Flow | -9.93M | -8.06M | 1.02M | 4.36B | -159.87M | -16.80M |
Diamond BioFund Inc. Peers Comparison
Overall Rating
- TW:690144Neutral
TW:657642Neutral
TW:661740Underperform
TW:653539Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6901 | 44Neutral | TWD 11.74B | 4.09 | ― | ― | ― | ― |
| TW:6576 | 42Neutral | TWD 11.52B | 519.28 | ― | ― | 6.41% | ― |
| TW:6617 | 40Underperform | TWD 15.11B | -92.22 | ― | ― | 11.66% | -72.96% |
| TW:6535 | 39Underperform | TWD 12.33B | -33.67 | ― | ― | -24.84% | 9.09% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6901 | Diamond BioFund Inc. | 14.00 | -4.30 | -23.50% | |
| TW:6467 | TAHO Pharmaceuticals Ltd | 230.00 | 56.50 | 32.56% | |
| TW:6535 | LUMOSA THERAPEUTICS CO LTD | 80.80 | -107.20 | -57.02% | |
| TW:6576 | Foresee Pharmaceuticals Co., Ltd. | 73.00 | -4.50 | -5.81% | |
| TW:6589 | EirGenix, Inc. | 51.70 | -22.80 | -30.60% | |
| TW:6617 | Gongwin Biopharm Holdings Co., Ltd. | 126.50 | 41.90 | 49.53% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026